Symptomatic patients with <1 cm² aortic valve area will benefit from an intervention regardless parameters such as flow and gradient, even if these are normal (or at least not severe). A valve replacement will be indicated without question (either surgical or percutaneous) in patients with >40 mHg mean gradient or low gradient justified by low<a href="https://solaci.org/en/2018/09/27/aortic-stenosis-with-normal-flow-low-gradient-should-we-intervene-or-wait/" title="Read more" >...</a>
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Lee Benson, entitled “Neonatal Aortic Stenosis Is a Surgical Disease… Really, in 2018?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Frailty is the patient’s diminished capacity to recover after pathological or iatrogenic processes. It has a fundamental role when considering valve replacement, be it surgical (SAVR) or transcatheter (TAVR). This was clearly observed in the PARTNER I and Core-Valve Pivotal trials, which showed that despite a 95% technical success, 2 in 5 patients showed poor quality<a href="https://solaci.org/en/2017/08/16/how-to-standardize-frailty-in-aortic-stenosis-patients/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic stenosis can present different hemodynamic patterns, such as low flow and low gradient with reduced or preserved ventricular function. However, evidence on the evolution of different hemodynamic patterns after transcatheter aortic valve replacement (TAVR) is limited. This study consisted in a retrospective analysis of 368 patients who underwent TAVR. The population was divided in<a href="https://solaci.org/en/2017/07/26/how-can-we-classify-aortic-stenosis-in-patients-who-underwent-tavr-2/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. It is known that patients with low gradient aortic stenosis show poor evolution with medical treatment and, in addition, present high mortality rate with surgery. As regards TAVR, a far simpler procedure compared to surgery, there is contradicting evidence; while some studies claim it holds comparable risks, others have found<a href="https://solaci.org/en/2017/06/01/low-gradient-aortic-stenosis-wont-improve-with-tavr/" title="Read more" >...</a>
Ventricular dysfunction and moderate aortic stenosis are more frequent with advancing age and often coexist. Afterload reduction is one of the main pillars of pharmacological treatment of heart failure, and aortic stenosis (even that of moderate severity) increases the afterload. Nowadays, aortic valve replacement is only formally indicated for symptomatic severe aortic stenosis. This<a href="https://solaci.org/en/2017/05/25/moderate-aortic-stenosis-and-ventricular-dysfunction-should-valve-replacement-come-sooner/" title="Read more" >...</a>
This work studies the natural history of aortic stenosis and the optimal timing to intervene elderly patients with asymptomatic severe aortic stenosis. This disease is increasingly misdiagnosed in the elderly population, and this goes hand in hand with enhanced therapeutic options. Prior studies on the natural history of this disease were made on<a href="https://solaci.org/en/2017/02/14/asymptomatic-severe-aortic-stenosis-in-the-elderly-when-to-intervene/" title="Read more" >...</a>
Patients with low-flow, low-gradient severe symptomatic aortic stenosis associated with severe impairment of the left ventricular systolic function have shown acceptable outcomes after transcatheter aortic valve replacement (TAVR), according to the multicenter TOPAS-TAVI registry, which demonstrated a relatively low 30-day mortality rate. Considering the very high risk presented by this population involved, a 30-day<a href="https://solaci.org/en/2017/01/06/tavr-in-low-flow-low-gradient-aortic-stenosis-and-severe-impairment-of-systolic-function/" title="Read more" >...</a>
Left Main Disease angioplasty in patients with severe aortic stenosis Javier Ibáñez, MD
